QQQ   308.28 (+2.45%)
AAPL   148.95 (+2.42%)
MSFT   259.42 (+2.64%)
META   182.68 (+19.31%)
GOOGL   106.68 (+6.22%)
AMZN   110.09 (+4.70%)
TSLA   189.64 (+4.54%)
NVDA   213.86 (+2.12%)
NIO   12.10 (+0.00%)
BABA   110.10 (-2.41%)
AMD   85.67 (+1.22%)
T   20.10 (-0.40%)
MU   63.10 (+0.80%)
F   14.21 (+3.05%)
CGC   3.16 (+2.60%)
GE   82.26 (-0.07%)
DIS   110.50 (+1.01%)
AMC   6.18 (+8.23%)
PFE   43.83 (-0.32%)
PYPL   86.61 (+4.46%)
NFLX   361.64 (-0.10%)
QQQ   308.28 (+2.45%)
AAPL   148.95 (+2.42%)
MSFT   259.42 (+2.64%)
META   182.68 (+19.31%)
GOOGL   106.68 (+6.22%)
AMZN   110.09 (+4.70%)
TSLA   189.64 (+4.54%)
NVDA   213.86 (+2.12%)
NIO   12.10 (+0.00%)
BABA   110.10 (-2.41%)
AMD   85.67 (+1.22%)
T   20.10 (-0.40%)
MU   63.10 (+0.80%)
F   14.21 (+3.05%)
CGC   3.16 (+2.60%)
GE   82.26 (-0.07%)
DIS   110.50 (+1.01%)
AMC   6.18 (+8.23%)
PFE   43.83 (-0.32%)
PYPL   86.61 (+4.46%)
NFLX   361.64 (-0.10%)
QQQ   308.28 (+2.45%)
AAPL   148.95 (+2.42%)
MSFT   259.42 (+2.64%)
META   182.68 (+19.31%)
GOOGL   106.68 (+6.22%)
AMZN   110.09 (+4.70%)
TSLA   189.64 (+4.54%)
NVDA   213.86 (+2.12%)
NIO   12.10 (+0.00%)
BABA   110.10 (-2.41%)
AMD   85.67 (+1.22%)
T   20.10 (-0.40%)
MU   63.10 (+0.80%)
F   14.21 (+3.05%)
CGC   3.16 (+2.60%)
GE   82.26 (-0.07%)
DIS   110.50 (+1.01%)
AMC   6.18 (+8.23%)
PFE   43.83 (-0.32%)
PYPL   86.61 (+4.46%)
NFLX   361.64 (-0.10%)
QQQ   308.28 (+2.45%)
AAPL   148.95 (+2.42%)
MSFT   259.42 (+2.64%)
META   182.68 (+19.31%)
GOOGL   106.68 (+6.22%)
AMZN   110.09 (+4.70%)
TSLA   189.64 (+4.54%)
NVDA   213.86 (+2.12%)
NIO   12.10 (+0.00%)
BABA   110.10 (-2.41%)
AMD   85.67 (+1.22%)
T   20.10 (-0.40%)
MU   63.10 (+0.80%)
F   14.21 (+3.05%)
CGC   3.16 (+2.60%)
GE   82.26 (-0.07%)
DIS   110.50 (+1.01%)
AMC   6.18 (+8.23%)
PFE   43.83 (-0.32%)
PYPL   86.61 (+4.46%)
NFLX   361.64 (-0.10%)
NASDAQ:CTSO

Cytosorbents - CTSO Stock Forecast, Price & News

$3.05
+0.02 (+0.66%)
(As of 02/2/2023 09:47 AM ET)
Add
Compare
Today's Range
$3.05
$3.10
50-Day Range
$1.03
$3.03
52-Week Range
$1.03
$4.15
Volume
1,871 shs
Average Volume
102,917 shs
Market Capitalization
$133.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.75

Cytosorbents MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
88.5% Upside
$5.75 Price Target
Short Interest
Healthy
1.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Cytosorbents in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$25,389 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.83) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

500th out of 1,030 stocks

Surgical & Medical Instruments Industry

53rd out of 105 stocks


CTSO stock logo

About Cytosorbents (NASDAQ:CTSO) Stock

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

CTSO Stock News Headlines

Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
Analyzing Cytosorbents (NASDAQ:CTSO) & DarioHealth (NASDAQ:DRIO)
StockNews.com Downgrades Cytosorbents (NASDAQ:CTSO) to Sell
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
Cytosorbents Corporation (CTSO)
See More Headlines
Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

CTSO Company Calendar

Last Earnings
11/04/2021
Today
2/02/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTSO
Employees
221
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.75
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+88.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,560,000.00
Net Margins
-114.61%
Pretax Margin
-116.65%

Debt

Sales & Book Value

Annual Sales
$43.17 million
Book Value
$1.44 per share

Miscellaneous

Free Float
40,581,000
Market Cap
$133.10 million
Optionable
Optionable
Beta
0.76

Key Executives

  • Dr. Phillip P. Chan M.D.Dr. Phillip P. Chan M.D. (Age 53)
    Ph.D., CEO & Director
    Comp: $667.47k
  • Mr. Vincent J. Capponi M.S. (Age 65)
    MS, Pres & COO
    Comp: $539.29k
  • Ms. Kathleen P. Bloch CPAMs. Kathleen P. Bloch CPA (Age 68)
    CPA, M.B.A., MBA, CFO & Sec.
    Comp: $462.11k
  • Dr. Efthymios N. Deliargyris FACC (Age 54)
    FESC, FSCAI, M.D., Chief Medical Officer
    Comp: $521.61k
  • Ms. Terri Anne Powers M.B.A.
    VP of Investor Relations & Corp. Communications
  • Dr. Christian Steiner M.D.
    Exec. VP of Sales & Marketing
  • Mr. Christopher Cramer MBA
    MS, VP of Bus. Devel.
  • Dr. Robert H. Bartlett M.D. (Age 84)
    Co-Chairman of Cardiac Surgery Advisory Board & Consultant













CTSO Stock - Frequently Asked Questions

Should I buy or sell Cytosorbents stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTSO shares.
View CTSO analyst ratings
or view top-rated stocks.

What is Cytosorbents' stock price forecast for 2023?

1 Wall Street research analysts have issued 12 month price targets for Cytosorbents' shares. Their CTSO share price forecasts range from $5.50 to $6.00. On average, they expect the company's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 89.8% from the stock's current price.
View analysts price targets for CTSO
or view top-rated stocks among Wall Street analysts.

How have CTSO shares performed in 2023?

Cytosorbents' stock was trading at $1.55 at the start of the year. Since then, CTSO shares have increased by 95.5% and is now trading at $3.03.
View the best growth stocks for 2023 here
.

When is Cytosorbents' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our CTSO earnings forecast
.

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) posted its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.03. The medical research company earned $9.76 million during the quarter, compared to analyst estimates of $9.96 million. Cytosorbents had a negative net margin of 114.61% and a negative trailing twelve-month return on equity of 80.80%. During the same period last year, the firm posted ($0.02) EPS.

What guidance has Cytosorbents issued on next quarter's earnings?

Cytosorbents updated its fourth quarter 2022 earnings guidance on Tuesday, January, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9.40 million-$9.40 million, compared to the consensus revenue estimate of $8.90 million.

What is Phillip Chan's approval rating as Cytosorbents' CEO?

11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend.

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (2.26%), Eudaimonia Partners LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Al Kraus, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi.
View institutional ownership trends
.

How do I buy shares of Cytosorbents?

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $3.03.

How much money does Cytosorbents make?

Cytosorbents (NASDAQ:CTSO) has a market capitalization of $132.23 million and generates $43.17 million in revenue each year. The medical research company earns $-24,560,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How many employees does Cytosorbents have?

The company employs 221 workers across the globe.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.cytosorbents.com. The medical research company can be reached via phone at (732) 329-8885, via email at avogel@cytosorbents.com, or via fax at 732-329-8650.

This page (NASDAQ:CTSO) was last updated on 2/2/2023 by MarketBeat.com Staff